Security record · archived quarter
MLTX
MoonLake Immunotherapeutics · Healthcare · Biotechnology
7Tracked holders
—Δ holders
8.40MShares held
$369.30MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 59 | +3 | 21.61M | $421.37M | +4 | −1 |
| Q1 2026 | 59 | +5 | 21.19M | $393.03M | +8 | −3 |
| Q4 2025 | 55 | +1 | 18.04M | $237.83M | +3 | −2 |
| Q3 2025 | 15 | +2 | 5.30M | $38.02M | +3 | −1 |
| Q2 2025 | 10 | -1 | 11.33M | $534.65M | +1 | −2 |
| Q1 2025 | 8 | 0 | 5.66M | $221.05M | +2 | −2 |
| Q4 2024 | 8 | 0 | 7.28M | $394.17M | +1 | −1 |
| Q3 2024 | 7 | 0 | 7.26M | $366.27M | — | — |
| Q2 2024 | 7 | — | 8.40M | $369.30M | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 2.56M | — | $112.63M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 2.27M | — | $99.62M | 0.1% | n/c | 1 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 2.27M | — | $99.62M | 0.1% | n/c | 1 | SEC ↗ |
| 4 | Adage Capital Partners ✦ | 1.82M | — | $80.25M | 0.1% | n/c | 1 | SEC ↗ |
| 5 | Marshall Wace ✦ | 1.10M | — | $48.31M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 372.66K | — | $16.39M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 372.66K | — | $16.39M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 372.66K | — | $16.39M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 372.66K | — | $16.39M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Millennium Management ✦ | 216.96K | — | $9.54M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Geode Capital Management ✦ (passive) | 58.50K | — | $2.57M | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 145 holders, 61.96M shares, $1.12B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API